Molina Healthcare, Inc.

▲ Bull Case

• ◆2026 capitation rates fully reflect the higher-acuity post-redetermination Medicaid population; MLR recovers rapidly to 87–88% in H1 2026, driving EPS recovery to $20–22 and multiple re-rating to 13x, implying a price target of ~$275 (+48.6%).
• ◆Operating leverage is extreme: at ~$45–47B in revenue, each 1-percentage-point MLR improvement equals ~$450M in pre-tax income; a 5-point recovery (93.5%→88.5%) generates a ~$2.25B pre-tax swing equating to ~$33/share in EPS improvement.
• ◆Zubretsky has executed this exact playbook before — the 2017–2018 turnaround from near-bankruptcy to $20+ EPS used the same tools (tight medical management, selective market exits, disciplined bidding), providing a credible historical precedent for a successful recovery.

▼ Bear Case

• ◆Capitation rate catch-up is insufficient; MLR remains 91–93% in FY2026 (second consecutive crisis year), statutory capital falls further under stress, and the stock re-rates to ~$105 (-43.2%), producing meaningful capital destruction with no dividend cushion.
• ◆Federal per-capita Medicaid caps — though not currently enacted — represent a structural risk that could fundamentally alter Molina's business model, weakening its leverage with states and compressing long-term margin structure; the severe scenario (5% probability) implies a price of ~$50 (-73%).
• ◆Statutory capital is already at the lower bound of the target range after a negative OCF year; one more year of elevated claims or adverse development could breach minimum requirements in high-revenue states, triggering regulatory intervention, forced capital injection, or market exit.

“Most analysts are treating the FY2025 MLR crisis as a valuation event (stock down -50%+ from highs) and are in a 'wait and see' posture for confirmation. The key debate centers on whether the 2026 capitation rate resets are sufficient and fast enough to normalize the MLR, or whether the higher-acuity post-redetermination population represents a permanent shift that rates will only partially offset. The actual mispricing opportunity — if it exists — is at $150–165 where the entry implies only ~10x partial-recovery EPS and the R/R improves substantially. At $185, the market appears to be pricing the uncertainty near-correctly, making MOH neither obviously cheap nor obviously expensive without Q1 2026 MLR confirmation.”

• ◆Q1 2026 MLR result — already available in filed 10-Q (April 23, 2026); single most important data point for the entire thesis
• ◆Q2 2026 earnings release (July 2026) confirming MLR sustainability into second quarter of new rate year
• ◆August 2026 federal Medicaid reform legislative update — particularly any movement toward or away from per-capita cap structures
• ◆Q3 2026 state capitation renewal announcements for FY2027 rates confirming multi-year rate normalization trajectory
• ◆Free cash flow / OCF turning positive in 2026 — confirming earnings recovery is translating to cash generation and relieving statutory capital pressure

• ◆Q1 2026 MLR >92% — indicates rate resets insufficient and the acuity problem is deeper than expected; triggers exit
• ◆Federal per-capita Medicaid caps enacted — structurally alters business model; raises severe scenario probability from 5% to 20%+
• ◆Statutory capital falls below required minimum in any major state (CA, TX, FL) — regulatory intervention, forced capital injection, or market exit
• ◆Second consecutive year of MLR >91% (FY2026) — extends capital erosion cycle by another year and raises bear scenario probability above 35%
• ◆CEO Zubretsky departure before FY2026 recovery is confirmed — removes primary execution anchor and requires from-scratch evaluation of replacement's state Medicaid relationships